Erratum: P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83))

Stephen Hanauer; Marla Dubinsky; Jason Coarse; David Rubin

doi:10.1097/01.MIB.0000442973.49982.02

Erratum: P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83))

Stephen Hanauer, Marla Dubinsky, Jason Coarse, David Rubin

Medicine, Gastroenterology Division

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	E9
Journal	Inflammatory bowel diseases
Volume	20
Issue number	2
DOIs	https://doi.org/10.1097/01.MIB.0000442973.49982.02
State	Published - Feb 2014

ASJC Scopus subject areas

Immunology and Allergy
Gastroenterology

Access to Document

10.1097/01.MIB.0000442973.49982.02

Cite this

@article{99c81e193d134c249f0494fff8bb9ce5,

title = "Erratum: P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83))",

author = "Stephen Hanauer and Marla Dubinsky and Jason Coarse and David Rubin",

year = "2014",

month = feb,

doi = "10.1097/01.MIB.0000442973.49982.02",

language = "English (US)",

volume = "20",

pages = "E9",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Erratum : P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83)). / Hanauer, Stephen; Dubinsky, Marla; Coarse, Jason; Rubin, David.

In: Inflammatory bowel diseases, Vol. 20, No. 2, 02.2014, p. E9.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum

T2 - P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83))

AU - Hanauer, Stephen

AU - Dubinsky, Marla

AU - Coarse, Jason

AU - Rubin, David

PY - 2014/2

Y1 - 2014/2

UR - http://www.scopus.com/inward/record.url?scp=84893799235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893799235&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000442973.49982.02

DO - 10.1097/01.MIB.0000442973.49982.02

M3 - Comment/debate

AN - SCOPUS:84893799235

VL - 20

SP - E9

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -

Erratum: P-147 Clinical efficacy of certolizumab pegol in patients with Crohn's disease based on moderate versus severe activity in the PRECiSE-2 trial (Inflammatory Bowel Diseases (2013) 19 (S83))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this